Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020


Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time. The call had previously been scheduled for 8:00 a.m. ET. All other aspects of the call remain unchanged.

The Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020.

To participate in the conference call, dial (866) 762-3111 (USA) or (210) 874-7712 (International), conference ID 3571658 shortly before 7:30 a.m. ET. The audio webcast can be accessed on the Investor page of http://ir.alexion.com and an archived version will be available for a limited time following the presentation.

[ALXN-G]


These press releases may also interest you

at 02:11
Xiao-I Corporation ("Xiao-I" or "the Company"), a leading artificial intelligence company, announced today that that the Company's full year 2023 financial results will be released before the U.S. market opens on Tuesday April 30, 2024. The Company...

at 02:00
OKX, a leading crypto exchange and Web3 technology company, has issued updates for April 26, 2024. OKX to Expand Spot Trading Options...

at 02:00
World-leading vaping brands ELFBAR and LOST MARY announced the latest outcomes from their continued global action against...

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...

at 02:00
Nebula Energy and Gogoro Inc , a global technology leader in battery-swapping ecosystems that enable sustainable mobility solutions for cities,...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...



News published on and distributed by: